The FDA has approved a molecular assay that helps determine blood compatibility for transfusion patients by identifying genetic markers that code for red blood cell antigens.
The ID Core XT blood group genotyping kit can streamline blood compatibility testing and offers clinicians another alternative to antisera blood testing, Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, said in a statement. “We know that DNA testing holds great promise to provide more informative, accurate, and cost-effective methods that can enhance patient care,” he noted.
Voelker R. Blood Group Genotyping Test Goes Beyond A, B, and O. JAMA. 2018;320(19):1970. doi:10.1001/jama.2018.17838
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: